

PRESS RELEASE - APRIL 2022

# RESISTELL INITIATES A RESEARCH PROJECT FUNDED BY AN INDEPENDENT GRANT FROM PFIZER AG



Press release - April 2022

# Resistell initiates a research project funded by an independent grant from Pfizer AG

Resistell, a TOP10 Swiss Start-up addressing the problem of speed in the diagnostics of antibiotic resistance, is pleased to announce they have initiated a research project to assess the applicability of Resistell's antibiotic susceptibility test (AST) to a novel antibiotic. The project is funded by an independent grant from Pfizer AG.

Resistell, an EPFL spin-off, was incorporated in 2018 to develop the world's fastest antibiotic susceptibility test based on analysis of nano-scale vibrations of living cells. Resistell's first diagnostic product, Phenotech, currently under clinical validation for bacteremia and sepsis, is a compact and user friendly device, with single use sensors and a cloud-based automated data analysis platform. It provides AST

results for Gram-negative bacteria in as little as 4 hours. The device achieved 100% accuracy in the pilot clinical study.

The goal of the research project is to provide a pre-clinical proof of concept of Resistell's AST applicability for a novel antibiotic. The project is funded by an independent grant from Pfizer AG.

Multi-drug resistance is one of the biggest global health challenges today, with insufficient availability of diagnostics and new effective antibiotics playing a major contributing factor. The positive outcome of this project may contribute to a paradigm shift in the management of infectious diseases and open the door to informed, diagnostics based treatment decisions.

*"Targeted and precise use of antibiotics is ever more important in the light of constantly increasing multidrug-resistant infections. Resistell's rapid phenotypic AST enables adequate antibiotic therapy for critically ill patients, which not only saves lives but also extends the lifetime of novel antibiotics that are so scarce nowadays."*

says Dr. Danuta Cichocka, Resistell CEO.



